To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults after taking the drugs with food (fed state).

Inclusion Criteria:

• Healthy adult volunteers aged 19 to 50 years at the time of screening.

• Body mass index (BMI) between 18.0 and 30.0 kg/m², inclusive.

  • Male subjects must weigh ≥50 kg.
  • Female subjects must weigh ≥45 kg.

• No clinically significant congenital or chronic diseases requiring treatment, based on medical history and physical examination.

• Clinically acceptable results from laboratory tests (e.g., hematology, biochemistry, serology, urinalysis) and electrocardiogram (ECG) at screening, as determined by the investigator.

• Willing to use medically accepted contraception (excluding hormonal methods) from the first dose until 7 days after the last dose, and agrees not to donate sperm or eggs during this period.

• Able and willing to provide written informed consent after receiving a full explanation of the study.

Exclusion Criteria:

• Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.

• Participation in any clinical trial involving investigational products within 6 months prior to the first dose.

• Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.

• History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).

• History of excessive alcohol consumption within 1 month prior to the first dose:

  • >21 drinks/week for males, >14 drinks/week for females (1 drink = 50 mL soju, 30 mL whiskey, or 250 mL beer)

• Known hypersensitivity to any component of the investigational product.

• Clinically significant renal, hepatic, cardiovascular, respiratory, metabolic, or infectious diseases, including but not limited to:

  • Moderate to severe renal impairment (eGFR or creatinine clearance <45 mL/min)
  • Dialysis
  • Acute or unstable heart failure
  • Acute myocardial infarction, septicemia, or shock
  • Type 1 diabetes, metabolic acidosis, or history of diabetic ketoacidosis
  • Major surgery planned during the study (except minor procedures not affecting food or fluid intake)
  • Severe infections, trauma, or nutritional deficiencies

• Positive pregnancy test or currently breastfeeding (for female subjects).

• History of significant psychiatric illness.

• Determined by the investigator to be unsuitable for the study for any other reason.